We are live on ! Find out more
TXMD icon

TherapeuticsMD
TXMD

142 hedge funds and large institutions have $252M invested in TherapeuticsMD in 2020 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 32 increasing their positions, 48 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more capital invested

Capital invested by funds: $190M → $252M (+$61.5M)

24% more call options, than puts

Call options by funds: $1.94M | Put options by funds: $1.57M

0.05% more ownership

Funds ownership: 1.12% → 1.17% (+0.05%)

5% less funds holding

Funds holding: 149 → 142 (-7)

30% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 23

33% less repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 48

Holders
142
Holders Change
-7
Holders Change %
-4.7%
% of All Funds
2.86%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
16
Increased
32
Reduced
48
Closed
23
Calls
$1.94M
Puts
$1.57M
Net Calls
+$371K
Net Calls Change
+$580K

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$7.41M
2
Handelsbanken Fonder
Handelsbanken Fonder
Sweden
+$3.99M
3
SAM
Storebrand Asset Management
Norway
+$2.65M
4
Goldman Sachs
Goldman Sachs
New York
+$2.56M
5
IM
Islet Management
New York
+$2.39M

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$4.1M
2
Millennium Management
Millennium Management
New York
-$1.01M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$966K
4
Squarepoint
Squarepoint
New York
-$879K
5
Ameriprise
Ameriprise
Minnesota
-$799K

TXMD Hedge Fund Activity: Q3 2020 in Review

142 of the 4,969 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q3 2020, worth a combined $252M — up 32% from $190M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of TXMD and 16 opened new positions — a net loss of 7 holders — while 48 trimmed existing stakes and 32 added.

The largest buyer was Rubric Capital Management (New York), adding an estimated $7.41M. The largest seller was BlackRock, cutting an estimated $4.1M.

  • 142 institutional investors held TherapeuticsMD (TXMD) as of Q3 2020, down from 149 in Q2 2020.
  • Funds reported $252M of TherapeuticsMD stock for Q3 2020, up 32% quarter-over-quarter.
  • 16 funds opened new TherapeuticsMD positions in Q3 2020 and 23 closed out, a net change of -7 holders.
  • The largest TherapeuticsMD buyer in Q3 2020 was Rubric Capital Management (New York), an estimated $7.41M added.
  • The largest TherapeuticsMD seller in Q3 2020 was BlackRock, an estimated $4.1M sold.

Based on aggregated 13F filings for Q3 2020.